• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CTLA-4 and ovarian cancer residual tumors: the dark side of debulking surgery.

作者信息

Abdalla Mohnad, El-Arabey Amr Ahmed, Gai Zhongtao

机构信息

Pediatric Research Institute, Children's Hospital Affiliated to Shandong University, Jinan, 250022, Shandong, China.

Shandong Provincial Clinical Research Center for Children's Health and Disease, Jinan, 250022, Shandong, China.

出版信息

Hum Cell. 2023 Nov;36(6):2281-2283. doi: 10.1007/s13577-023-00976-6. Epub 2023 Aug 24.

DOI:10.1007/s13577-023-00976-6
PMID:37615906
Abstract
摘要

相似文献

1
CTLA-4 and ovarian cancer residual tumors: the dark side of debulking surgery.细胞毒性T淋巴细胞相关抗原4与卵巢癌残留肿瘤：肿瘤细胞减灭术的负面影响
Hum Cell. 2023 Nov;36(6):2281-2283. doi: 10.1007/s13577-023-00976-6. Epub 2023 Aug 24.
2
Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands: A nationwide study.荷兰低级别浆液性卵巢癌的分期、治疗和生存情况：一项全国性研究。
Acta Obstet Gynecol Scand. 2023 Mar;102(3):246-256. doi: 10.1111/aogs.14518. Epub 2023 Feb 3.
3
Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence.高级别浆液性卵巢癌的初始减瘤手术：当前证据
Ann Transl Med. 2020 Dec;8(24):1707. doi: 10.21037/atm-20-1620.
4
The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer.新辅助化疗和肿瘤细胞减灭术对晚期卵巢癌生存的影响。
Gynecol Oncol. 2014 Sep;134(3):462-7. doi: 10.1016/j.ygyno.2014.07.004. Epub 2014 Jul 12.
5
A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.一种新的晚期卵巢癌间歇肿瘤减灭术后残留病灶分类方法，可更好地区分肿瘤学结局。
Am J Obstet Gynecol. 2019 Oct;221(4):326.e1-326.e7. doi: 10.1016/j.ajog.2019.05.006. Epub 2019 May 10.
6
Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.预测晚期原发性高级别浆液性卵巢癌患者手术结局的生物标志物。我们做到了吗？卵巢癌前瞻性生物库分析。
Gynecol Oncol. 2022 Aug;166(2):334-343. doi: 10.1016/j.ygyno.2022.06.010. Epub 2022 Jun 21.
7
Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers.晚期低级别浆液性卵巢癌：两个大型肿瘤中心手术及化疗管理的回顾性分析
Front Oncol. 2022 Sep 27;12:970918. doi: 10.3389/fonc.2022.970918. eCollection 2022.
8
Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.高级别晚期卵巢癌的初次肿瘤细胞减灭术与初次新辅助化疗：生存比较。
Radiol Oncol. 2018 Sep 11;52(3):307-319. doi: 10.2478/raon-2018-0030.
9
SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery.SOX2是晚期高级别浆液性卵巢癌患者减瘤手术后有残留病灶时复发和死亡的一个有前景的预测指标。
Mol Cell Oncol. 2020 Sep 5;7(6):1805094. doi: 10.1080/23723556.2020.1805094.
10
A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy.原发性肿瘤细胞减灭术与新辅助化疗治疗晚期浆液性卵巢癌患者的生存结果比较
Int J Gynecol Cancer. 2017 May;27(4):668-674. doi: 10.1097/IGC.0000000000000946.

引用本文的文献

1
Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer.审视高级别浆液性卵巢癌中免疫检查点疗法的证据。
Heliyon. 2024 Oct 5;10(20):e38888. doi: 10.1016/j.heliyon.2024.e38888. eCollection 2024 Oct 30.
2
Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration.区域免疫机制增强了腹腔内注射自体细胞癌疫苗的疗效。
Oncoimmunology. 2024 Dec 31;13(1):2421029. doi: 10.1080/2162402X.2024.2421029. Epub 2024 Nov 1.

本文引用的文献

1
The role of GATA3 in the metastasis of triple-negative breast cancer and high-grade serous ovarian cancer.GATA3在三阴性乳腺癌和高级别浆液性卵巢癌转移中的作用。
Hum Cell. 2022 Jul;35(4):1298-1300. doi: 10.1007/s13577-022-00706-4. Epub 2022 Apr 22.
2
GATA3 and stemness of high-grade serous ovarian carcinoma: novel hope for the deadliest type of ovarian cancer.GATA3与高级别浆液性卵巢癌的干性：最致命类型卵巢癌的新希望。
Hum Cell. 2020 Jul;33(3):904-906. doi: 10.1007/s13577-020-00368-0. Epub 2020 May 9.
3
Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
新辅助化疗后晚期高级别浆液性卵巢癌残留病灶的基因组分析。
Int J Cancer. 2020 Apr 1;146(7):1851-1861. doi: 10.1002/ijc.32729. Epub 2019 Nov 23.
4
MEXPRESS update 2019.美迅更新 2019.
Nucleic Acids Res. 2019 Jul 2;47(W1):W561-W565. doi: 10.1093/nar/gkz445.
5
A framework for understanding and targeting residual disease in oncogene-driven solid cancers.一种用于理解和靶向癌基因驱动的实体癌中残留疾病的框架。
Nat Med. 2016 May 5;22(5):472-8. doi: 10.1038/nm.4091.
6
The blockade of immune checkpoints in cancer immunotherapy.癌症免疫疗法中的免疫检查点阻断。
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239.
7
Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data.上皮性卵巢癌国际妇产科联盟（FIGO）分期 IIA-IV 期患者残余肿瘤大小的预后价值：OVCAD 数据分析。
Int J Gynecol Cancer. 2012 Mar;22(3):380-5. doi: 10.1097/IGC.0b013e31823de6ae.